Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy

Current Medical Research and Opinion

Volumn 31, Issue 4, 2015, Pages 757-765

  Modi, Ankita ^a   Siris, Ethel S ^b   Tang, Jackson ^c   Sen, Shuvayu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Department of Medicine   (United States)

^c Asclepius Analytics LLC   (United States)

Author keywords

Adherence; Compliance; Fracture risk; Healthcare costs; Healthcare utilization; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MIDDLE AGED; OSTEOPOROSIS; OUTPATIENT CARE; PATIENT COMPLIANCE; TREATMENT OUTCOME; TREATMENT REFUSAL; VERY ELDERLY; ECONOMICS; HEALTH CARE DELIVERY; HEALTH INSURANCE; MEDICATION COMPLIANCE; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDY; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; DELIVERY OF HEALTH CARE; DIPHOSPHONATES; FEMALE; HEALTH CARE COSTS; HUMANS; LOGISTIC MODELS; MANAGED CARE PROGRAMS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES; TERIPARATIDE;

EID: 84926333615     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1016605     Document Type: Article

References (29)

1. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 2014;11:2520-6
2. Budhia S, Mikyas Y, Tang M, Badamgarav E. Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization. Pharmacoeconomics 2012;30:147-70
3. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-75
4. Russo CA, Holmquist L, Elixhauser A. U.S. Hospitalizations Involving Osteoporosis and Injury,2006. HCUP Statistical Brief #76. Rockville, MD: Agency for Healthcare Research and Quality, July 2009. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb76.pdf [Last accessed 12 January 2015]
5. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. 2014 Issue, Version 1. Washington, DC. Available at: http://nof.org/files/nof/public/content/file/2791/upload/919.pdf [Last accessed 12 January 2015]
6. Briesacher BA, Andrade SE, Yood RA, Kahler KH. Consequences of poor compliance with bisphosphonates. Bone 2007;41:882-7
7. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-60
8. Wade SW, Curtis JR, Yu J, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 2012;50:870-5
9. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2008;19:811-18
10. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 2008;19:511-17
11. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and non-vertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22
12. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-8
13. Sunyecz JA, Mucha L, Baser O, et al. Impact of compliance and persistence with bisphosphonate therapy on health care costs and utilization. Osteoporos Int 2008;19:1421-9
14. Halpern R, Becker L, Iqbal SU, et al. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 2011;17:25-39
15. Eisenberg DF, Placzek H, Gu T, et al. Cost and consequences of noncompliance to oral bisphosphonate treatment. J Manag Care Spec Pharm 2015;21:56-65
16. th Congress. US Department of Health and Human Services. 1996. Available at: http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf [Last accessed 12 January 2015]
17. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
18. Curtis JR, Mudano AS, Solomon DH, et al. Identification and validation of vertebral compression fractures using administrative claims data. Med Care 2009;47:69-72
19. Martin KE, Yu J, Campbell HE, et al. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost. J Manag Care Pharm 2011;17:596-609
20. Viswanathan HN, Curtis JR, Yu J, et al. Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy. Appl Health Econ Health Policy 2012;10:163-73
21. US Department of Labor BoLS. Consumer Price Index - Chained Consumer Price Index. Available at: http://data.bls.gov/cgi-bin/surveymost [Last accessed 12 January 2015]
22. Patrick AR, Brookhart MA, Losina E, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab 2010;95:3251-9
23. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007;166:348-54
24. Curtis JR, Xi J, Westfall AO, et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 2009;47:334-41
25. Waalen J, Bruning AL, Peters MJ, Blau EM. A telephone-based intervention for increasing the use of osteoporosis medication: a randomized controlled trial. Am J Manag Care 2009;15:e60-70
26. Cuddihy MT, Amadio PC, Gabriel SE, et al. A prospective clinical practice intervention to improve osteoporosis management following distal forearm fracture. Osteoporos Int 2004;15:695-700
27. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009;20:2127-34
28. Solomon DH, Iversen MD, Avorn J, et al. Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 2012;172:477-83
29. Blouin J, Dragomir A, Fredette M, et al. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study. Osteoporos Int 2009;20:1571-81